Sex-related Differences in Outcome After Hybrid Coronary Revascularization
SEX-HYBRID
1 other identifier
observational
1,000
0 countries
N/A
Brief Summary
Hybrid coronary revascularization (HCR) has emerged as a favorable technique over traditional coronary artery bypass grafting (CABG) in a select group of patients with multivessel coronary artery disease (CAD). Till date, multiple individual studies comparing HCR with CABG have been carried out, but no data on the potential impact of sex on the outcome of HCR exist. To fill this knowledge gap, the investigators aim to perform an international collaborative multi-center study in order to examine gender differences in short-term and long-term outcomes among patients who underwent HCR or CABG.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2024
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 28, 2023
CompletedFirst Posted
Study publicly available on registry
September 5, 2023
CompletedStudy Start
First participant enrolled
January 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedNovember 29, 2023
November 1, 2023
1 year
August 28, 2023
November 27, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Incidence of Overall Mortality
All causes deaths
Up to 1 year
Incidence of Composite End-point
Cardiac death, myocardial infarction, stroke, bleeding
Up to 1 year
Interventions
It involves the combination of a sternal sparing left internal mammary artery (LIMA) bypass and percutaneous coronary intervention (PCI) with drug-eluting stents (DES) for non-left anterior descending (LAD) lesions. Through minimally invasive surgical techniques, HCR carries the potential for faster recovery postoperatively, fewer in-hospital complications, and lower utilization of healthcare resources, while providing the key benefits of LIMA-LAD grafting.
Eligibility Criteria
Patients with multivessel coronary artery disease and indication to cardiac surgery
You may qualify if:
- Patients with coronary artery disease and indication to cardiac surgery
You may not qualify if:
- Contraindications to cardiac surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 1 Year
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
August 28, 2023
First Posted
September 5, 2023
Study Start
January 1, 2024
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
November 29, 2023
Record last verified: 2023-11